Noah Labs Receives FDA Breakthrough Designation for AI Voice-Based Heart Failure Tool

Noah Labs has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its AI-powered voice diagnostic system, Noah Labs Vox™, designed to detect worsening heart failure at an early stage.

The software uses a machine learning algorithm to analyse short voice recordings of around five seconds. Subtle changes in speech patterns are assessed to identify early signs of clinical deterioration, potentially weeks before a patient requires hospitalisation. 

The tool is intended for remote, non-invasive monitoring and does not require additional hardware, making it suitable for use in both clinical and home settings.

The system has been developed using a large dataset of more than three million voice samples from heart failure patients. 

It has also been tested across multiple clinical trials in collaboration with leading medical institutions, including Mayo Clinic, UCSF, Charité Berlin, Maastricht University Medical Center, and Hospital Clínic de Barcelona.

Heart failure is a major cause of hospital admissions globally, and current monitoring methods can be limited by cost, invasiveness, and access to care. 

The new technology aims to support earlier clinical intervention, reduce hospitalisations, and improve patient outcomes, particularly in remote or resource-limited regions.

The FDA Breakthrough Device Designation is expected to support a faster regulatory pathway as the company prepares for further trials and potential commercialisation.